| PROfound研究——前列腺癌精准治疗新希望 |
| |
| 引用本文： | 黄后宝.PROfound研究——前列腺癌精准治疗新希望[J].金属学报,2020,25(2):144. |
| |
| 作者姓名： | 黄后宝 |
| |
| 作者单位： | 皖南医学院第一附属医院泌尿外科，芜湖 241001，安徽 |
| |
| 摘 要： | 转移性去势抵抗性前列腺癌（metastatic castrate-resistant prostate cancer,mCRPC）是前列腺癌发展的终末阶段。患者生存预后很差。尽管不断地有新的治疗手段出现，比如新型内分泌治疗以及紫杉醇类化疗，mCRPC患者的生存期依然很有限。奥拉帕利是一款聚腺苷酸二磷酸核糖基聚合酶（poly ADP-ribose polymerase,PARP）抑制剂，PARP酶在DNA修复中扮演着重要的角色。奥拉帕利已经获批用于卵巢癌和乳腺癌的治疗。目前，奥拉帕利用于mCRPC治疗的III期临床研究PROfound的结果在2019年的欧洲肿瘤内科学会（ESMO）年会与2020年的美国临床肿瘤学会-泌尿生殖系统肿瘤研讨会（ASCO-GU）已经发布。本文将带来PROfound研究的结果以及最新的结果更新。
|
| 关 键 词： | 转移性去势抵抗性前列腺癌 奥拉帕利 PROfound |
| 收稿时间： | 2020-02-21 |
| 修稿时间： | 2020-02-23 |
PROfound: A new hope for precise treatment of prostate cancer |
| |
| HUANG Houbao.PROfound: A new hope for precise treatment of prostate cancer[J].Acta Metallurgica Sinica,2020,25(2):144. |
| |
| Authors: | HUANG Houbao |
| |
| Affiliation: | Department of Urology, the First Affiliated Hospital of Wannan Medical College, Wuhu 241001, Anhui, China |
| |
| Abstract: | Metastatic castrate-resistant prostate cancer (mCRPC) is the last stage of prostate cancer. Although new hormonal agents and taxane-based chemotherapies occurred for mCRPC treatment, the overall survival of mCRPC patients is limited. Olaparib is an inhibitor of poly ADP-ribose polymerase (PARP), which has a key role in DNA damage response. It has been approved for ovarian cancer and breast cancer treatment. PROfound, a phase III clinical trial of olaparib in mCRPC treatment, has been reported in 2019 ESMO and 2020 ASCO-GU. In this paper, we will bring the results and updates of PROfound. |
| |
| Keywords: | metastatic castrate-resistant prostate cancer olaparib PROfound |
|
| 点击此处可从《金属学报》浏览原始摘要信息 |
|
点击此处可从《金属学报》下载全文 |
